A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.
Interventional
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.
Baseline up to Day 28 after last dose of study treatment
Yes
Pfizer CT.gov Call Center
Study Director
Pfizer
United States: Food and Drug Administration
A6181078
NCT00443534
May 2006
December 2011
Name | Location |
---|---|
Pfizer Investigational Site | Atlanta, Georgia 30342 |
Pfizer Investigational Site | Detroit, Michigan 48201 |
Pfizer Investigational Site | Springfield, Illinois 62701-1014 |
Pfizer Investigational Site | Houston, Texas 77030 |
Pfizer Investigational Site | Aurora, Colorado 80012 |
Pfizer Investigational Site | Clearwater, Florida 33761 |
Pfizer Investigational Site | Carmel, Indiana 46032 |
Pfizer Investigational Site | Westminster, Maryland 21157 |
Pfizer Investigational Site | Columbia, Missouri 65201 |
Pfizer Investigational Site | Las Vegas, Nevada 89128 |
Pfizer Investigational Site | Asheville, North Carolina 28801 |
Pfizer Investigational Site | Bartlesville, Oklahoma 74006 |
Pfizer Investigational Site | Kingston, Pennsylvania 18704-5535 |
Pfizer Investigational Site | Easley,, South Carolina 29640 |
Pfizer Investigational Site | Livingston, New Jersey 07039 |